Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)